Molecular Mechanisms Underpinning Sarcopenic Obesity

NCT06120647 | Unknown

• 1 other identifier: 2019-04016
• Study Type: observational
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

The coexistence of obesity and sarcopenia results in sarcopenic obesity, a high-risk geriatric condition associated with metabolic perturbations and several co-morbidities. Despite the rising numbers of older adults diagnosed with sarcopenic obesity, few studies have characterized this condition on the muscle cell and systemic level. This study sought to comprehensively assess the influence of sarcopenic obesity on muscle and blood-related parameters and compare it to non-sarocopenic obese and non-sarcopenic lean older adults.

Conditions

Sarcopenic Obesity; Obesity; Sarcopenia; Aging

Outcome Measures

Primary Outcomes (1)

• Fiber type-specific cell signalling

  This measure will be investigated during an experimental trial in which the participants are subjected to an acute bout of resistance exercise followed by the ingestion of essential amino acids (240 mg/kg lean mass). During this 3 hour time period, the participants will donate two muscle biopsies, one before exercise and the second one 1 hour after exercise. Cell signalling networks related to muscle mass regulation will be examined in these biopsy samples. The signal will be measured using Western blotting and the signal obtained is expressed in relation to baseline (adjusted volume intensity).

  1 hour after ingestion of essential amino acids and resistance exercise

Secondary Outcomes (5)

• Skeletal muscle fiber characteristics

  1 hour prior to ingestion of essential amino acids and resistance exercise

• Whole body muscle volume

  1 hour

• Whole body glucose tolerance

  2 hours

• Accelerometer-assessed physical activity levels

  1 week

• Isometric and isokinetic leg muscle strength

  1 hour

Study Arms (4)

Sarcopenic obesity

Age: 70-80 years Men, ALM/W \< 25.7 %, body fat % \> 35 Women, ALM/W \< 19.7 %, body fat % \> 40

Dietary Supplement: Essential amino acids (EAA)

Non-sarcopenic obese

Age: 70-80 years Men, ALM/W \> 25.7 %, body fat % \> 35 Women, ALM/W \> 19.7 %, body fat % \> 40

Dietary Supplement: Essential amino acids (EAA)

Non-sarcopenic lean

Age: 70-80 years Men, ALM \> 7.0 kg/m2, body fat % \< 25 Women, ALM \> 5.5 kg/m2, body fat % \< 32

Dietary Supplement: Essential amino acids (EAA)

Young lean

Age: 18-40 years Men, ALM \> 7.0 kg/m2, body fat % \< 25 Women, ALM \> 5.5 kg/m2, body fat % \< 32

Dietary Supplement: Essential amino acids (EAA)

Interventions

Essential amino acids (EAA) DIETARY_SUPPLEMENT

intake of 240 mg EAA per kg lean body mass after a resistance exercise session

Non-sarcopenic lean; Non-sarcopenic obese; Sarcopenic obesity; Young lean

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The elderly participants will be community-dwelling living in the greater Stockholm metropolitan area. Participants will be recruited through local senior clubs, online communities, advertisement and word of mouth. The young participants will be living in the greater Stockholm metropolitan area. Participants will be recruited through university forums, online communities, advertisement and word of mouth.

You may qualify if:

• Body fat % in accordance with previously defined criteria
• Free of smoking (since 10 years)
• Able to walk without assistance
• Able to perform bilateral leg extension exercise

You may not qualify if:

• History of or present disease of myocardial, vascular, endocrine, hepatic, renal, pulmonary or neuromuscular origin
• Uncontrolled hypo/hypertension
• Use of anticoagulants (Warfarin, Trombyl)
• Use of metformin or other anti-diabetic medications
• Poor appetite and unexplained weight loss (4,5 kg) over the past 6 months
• Active malignancy
• Present infection
• Dementia or delirium
• Other conditions that may interfere with the study protocol in the opinion of the PI

Sponsors & Collaborators

• The Swedish School of Sport and Health Sciences: lead

Study Sites (1)

The Swedish School of Sport and Health Sciences

Stockholm, 11433, Sweden

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

Skeletal muscle biopsies from m. vastus lateralis and venous blood samples

MeSH Terms

Conditions

Obesity; Sarcopenia

Interventions

Amino Acids, Essential

Condition Hierarchy (Ancestors)

Overweight; Overnutrition; Nutrition Disorders; Nutritional and Metabolic Diseases; Body Weight; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Muscular Atrophy; Neuromuscular Manifestations; Neurologic Manifestations; Nervous System Diseases; Atrophy; Pathological Conditions, Anatomical

Intervention Hierarchy (Ancestors)

Amino Acids; Amino Acids, Peptides, and Proteins

Study Officials

• William Apró, PhD

  The Swedish School of Sport and Health Sciences and Karolinska Institute, Stockholm Sweden

  PRINCIPAL INVESTIGATOR

Central Study Contacts

William Apró, PhD

CONTACT

08-120 538 67; william.apro@gih.se

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Associate Professor

Study Record Dates

• First Submitted: October 10, 2023
• First Posted: November 7, 2023
• Study Start: January 28, 2020
• Primary Completion: December 15, 2025
• Study Completion: December 30, 2025
• Last Updated: December 11, 2023

Record last verified: 2023-12

Locations

SE (1)